Promoted Content
Promoted Content

Find Approved Drugs for Pulmonary/Respiratory Diseases in Clinical Development in CHINA


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pretomanid

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: TB Alliance

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 16, 2020


            The partnership with Hongqi is part of TB Alliance’s global commercialization strategy for pretomanid as part of the BPaL regimen.